Aztreonam Lysine
Aztreonam lysine is an inhaled monobactam antibacterial agent. It is specifically formulated for inhalation to target Pseudomonas aeruginosa infections in the lungs of cystic fibrosis patients. It acts by binding to penicillin-binding proteins, thereby inhibiting bacterial cell wall synthesis and causing cell lysis.
Dosage by Body Weight
The standard dose for adults and pediatric patients aged 7 years and older is 75 mg administered by inhalation three times daily for a 28-day cycle, followed by 28 days off the drug. Doses should be taken at least 4 hours apart using the Altera Nebulizer System. It is not dosed based on body weight, and safety has not been established for patients under 7 years of age.
- Body Weight
- Below 5 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness in pediatric patients under 7 years of age have not been established.
- Body Weight
- 5-7 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness in pediatric patients under 7 years of age have not been established.
- Body Weight
- 8-10 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness in pediatric patients under 7 years of age have not been established.
- Body Weight
- 11-15 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness in pediatric patients under 7 years of age have not been established.
- Body Weight
- 16-20 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness in pediatric patients under 7 years of age have not been established. Patients aged 7 years and older receive a flat dose of 75 mg three times daily regardless of body weight.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not recommended | N/A | Safety and effectiveness in pediatric patients under 7 years of age have not been established. |
| 5-7 kg | Not recommended | N/A | Safety and effectiveness in pediatric patients under 7 years of age have not been established. |
| 8-10 kg | Not recommended | N/A | Safety and effectiveness in pediatric patients under 7 years of age have not been established. |
| 11-15 kg | Not recommended | N/A | Safety and effectiveness in pediatric patients under 7 years of age have not been established. |
| 16-20 kg | Not recommended | N/A | Safety and effectiveness in pediatric patients under 7 years of age have not been established. Patients aged 7 years and older receive a flat dose of 75 mg three times daily regardless of body weight. |
Formulation
Purpose
To improve respiratory symptoms in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infections.
Generic Name
Aztreonam lysineBranded Drug Names
Aztreonam Lysine is listed as a generic drug name. Common branded medicines that may contain the same active ingredient include:
Scheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.